United Therapeutics Prevails In Patent Litigation Against Liquidia

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that the United States District Court for the District of Delaware issued an opinion on October 1, 2026, that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics’ patent covering the use of inhaled treprostinil to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). 

The opinion was rendered in litigation concerning United Therapeutics’ U.S. Patent No. 11,826,327 (the ’327 patent), which relates to a method of improving exercise capacity in patients with PH-ILD by inhaling treprostinil at specific dosages. Specifically, the Court determined that Liquidia induces infringement of claims 1 and 14 of the ’327 patent by marketing Yutrepia® for PH-ILD. The Court also concluded that Liquidia failed to prove that those claims are invalid.

Steve Maebius of Foley & Lardner LLP led the team who prosecuted and secured the ‘327 patent on behalf of United Therapeutics, which formed the basis of the successful patent litigation.